Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer

Samankaltaisia teoksia

• First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
  Tekijä: Addeo, Alfredo, et al.
  Julkaistu: (2018)
• Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
  Tekijä: Chuang, Jody C., et al.
  Julkaistu: (2015)
• Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning
  Tekijä: Klempner, Samuel J., et al.
  Julkaistu: (2015)
• Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
  Tekijä: Sivignon, Marine, et al.
  Julkaistu: (2020)
• Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
  Tekijä: Gainor, Justin F., et al.
  Julkaistu: (2015)